Phase 2 Study of NU172 Anticoagulation in Patients Undergoing Coronary Artery Bypass Graft Surgery OFF-Pump.

Trial Profile

Phase 2 Study of NU172 Anticoagulation in Patients Undergoing Coronary Artery Bypass Graft Surgery OFF-Pump.

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs NU 172 (Primary)
  • Indications Thrombosis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms SNAP-CABG-OFF
  • Sponsors ARCA biopharma Inc
  • Most Recent Events

    • 09 Jun 2011 Planned end date changed from 1 Sep 2010 to 1 Sep 2013 as reported by ClinicalTrials.gov.
    • 09 Jul 2009 Planned end date changed from Mar 2010 to Sep 2010 as reported by ClinicalTrials.gov.
    • 19 Mar 2009 ARCA biopharma added as trial affiliate as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top